Anti-RET9 (RET or CDHF12 or CDHR16) antibody is validated on mouse tissue and recommended for immunofluorescence labeling, IHC, or western blot of materials from human and rodent tissues.
RET, abbreviated for “rearranged during transfection”, proto-oncogene encodes a receptor tyrosine kinase in human. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to RET stimulates receptor dimerization and activation of downstream signaling pathways. The RET protein consists in an N-terminal extracellular domain with four cadherin-like repeats and a cysteine-rich region, a transmembrane domain and a cytoplasmic tyrosine kinase domain.
Alternative splicing of the RET gene results in the production of 3 different isoforms of the RET protein: RET9, RET43 and RET51, which contain 9, 43 and 51 amino acids in their C-terminal tail respectively. RET9 and RET51 are the most common isoforms in which RET occurs.
This antibody was raised against the RET9 isoform.
Reviews
There are no reviews yet.